Business Wire

FourKites Partners with Sony Network Communications Europe to Help Enterprise Shippers Deliver Exceptional Customer Experience

9.11.2022 11:00:00 EET | Business Wire | Press release

Share

Today, leading supply chain visibility company FourKites announced a partnership with Sony Network Communications Europe. The partnership will integrate data from Visilion — Sony’s real-time cargo and asset tracking solution — with FourKites’ real-time, end-to-end supply chain visibility platform. This collaboration will help enterprise customers solve their most complex use cases. Now, customers will be able to view FourKites’ real-time data for shipments in transit and in the yard, together with Visilion’s granular real-time data on cargo location and condition to provide best-in-class estimated times of arrival (ETAs) and enhanced end-customer experiences.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221109005131/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

FourKites Partners with Sony Network Communications Europe to Help Enterprise Shippers Deliver Exceptional Customer Experience (Graphic: Business Wire)

Faced with ongoing global supply chain disruptions — including port congestion, port and rail strikes, global conflicts and more — businesses need more meaningful insights to mitigate preventable delays and damage, and to keep goods moving to their final destinations. Real-time visibility and actionable analytics regarding the location, temperature and status of shipments is critical, particularly for those in the Consumer Packaged Goods, Food & Beverage and Pharmaceutical industries, who ship products that require specific in-transit conditions to maintain quality.

“Businesses today require more high-quality, real-time supply chain data,” said Nimesh Patel, vice president of global alliances and partnerships at FourKites. “The Visilion solution from Sony provides an extra layer of granular data about the contents of containers and status of sensitive and/or temperature-controlled shipments. Our partnership will ensure that this data becomes more accessible than ever to businesses around the world.”

Visilion, Sony’s real-time cargo and asset tracking solution, offers industry-leading shock, tilt and temperature detection capabilities, among others, to ensure that goods are handled properly and maintained at the right temperature and humidity during transit, thereby mitigating losses. This functionality, combined with FourKites’ market-leading Dynamic ETA® across all modes, provides shippers with complete visibility into potential disruptions and product loss for goods in transit. In addition, FourKites’ international tracking capabilities, together with Visilion sensor data, provide an added dimension of granular visibility into ocean containers that often move through complicated, multi-stop journeys.

“FourKites’ shared commitment to industry-leading innovation, product quality and industry collaboration made them the obvious partner for us,” said Erik Lund, Head of Tracking Division, Sony Network Communications Europe. “We look forward to working together to provide our mutual customers with integrated supply chain data to fuel better decision-making and, ultimately, more efficient supply chain operations — in Europe and around the world.”

Over the last year, FourKites has experienced record growth in the European, Middle Eastern and African (EMEA) markets, achieving 97% growth in shipments YoY as of October 2022. The number of customers tracking loads with FourKites in EMEA grew 40% in the same time period, while the number of carriers tracking shipments grew by 50% in the same period.

About FourKites

Leading supply chain visibility platform FourKites® extends visibility beyond transportation into yards, warehouses, stores and beyond. Tracking more than 3 million shipments daily across road, rail, ocean, air, parcel and last mile, and reaching over 210 countries and territories, FourKites combines real-time data and powerful machine learning to help companies digitise their end-to-end supply chains. More than 1,200 of the world’s most recognised brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit https://www.fourkites.com/.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Scott Johnston
European PR Director for FourKites
+31 62 147 8442
scott.johnston@fourkites.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye